A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers

Trial Profile

A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs M 6620 (Primary) ; Topotecan
  • Indications Cervical cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Nov 2017 Planned End Date changed from 30 Oct 2020 to 30 Oct 2025.
    • 12 Jul 2017 Planned number of patients changed from 55 to 70.
    • 04 May 2017 Planned primary completion date changed from 31 May 2018 to 31 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top